Colleen Tupper Sells 10,445 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.00, for a total value of $58,470.00.

Collegium Pharmaceutical Stock Up 1.2 %

NASDAQ COLL opened at $29.46 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The stock’s 50 day moving average is $30.85 and its two-hundred day moving average is $32.96. The company has a market capitalization of $927.58 million, a price-to-earnings ratio of 12.70 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of COLL. New Age Alpha Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $40,000. TD Private Client Wealth LLC raised its position in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV raised its position in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Virtus Fund Advisers LLC raised its position in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 316 shares during the last quarter.

Wall Street Analyst Weigh In

COLL has been the topic of a number of recent analyst reports. Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.